A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the efficacy of escitalopram in treating depression in HIV seropositive women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Antidepressants on Sexual Functioning

NCT00051259

Major Depressive Disorder (MDD)

COMPLETED PHASE3

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252330

Major Depressive Disorder

COMPLETED PHASE3

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552

Major Depressive Disorder (MDD)

TERMINATED PHASE3

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

NCT00220701

Dysthymic Disorder

COMPLETED PHASE4

Escitalopram in Adult Patients With Major Depressive Disorder

NCT00668525

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To determine the efficacy of escitalopram in treating depression in HIV seropositive women.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sugar Pill

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo daily for duration of double-blind portion of trial

Active Drug

Escitalopram tablet, 10mg, daily, 9 weeks.

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

Escitalopram 10 mg po daily for duration of double-blind portion of trial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Placebo daily for duration of double-blind portion of trial

Intervention Type DRUG

Escitalopram

Escitalopram 10 mg po daily for duration of double-blind portion of trial

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of major depression based on DSM-IV criteria;
* age 18-70 years;
* Greater than 15 on MADRS for severity of depression;
* HIV seropositive;
* no new antiviral medications over the past 2 months;
* involved in active treatment for HIV disease,
* negative serum pregnancy test
* Those subjects who are actively being treated for depression but show no improvement as defined by self-reported failure to improve with current treatment or residual depression as demonstrated by a MADRS of 15 or greater will be asked to participate in the study as well.

Exclusion Criteria

* The presence of an active and significant psychiatric disease other than Major Depressive Disorder as diagnosed on MINI in the last 3 months;
* meeting DSM-IV criteria for an Axis I disorder within the last three months, or meeting criteria for substance abuse within the last 12 months;
* current pregnancy or lactation if breast feeding;
* history of hypersensitivity, intolerance, or contraindication to LEX;
* baseline creatinine of 2.5 or greater;
* patients taking anticoagulants;
* history of diagnosed gastric or duodenal ulcer;
* history within past year of bleeding or clotting diathesis;
* lifetime history of myocardial infarction or cerebrovascular accident;
* history of surgery within the past 3 months;
* inability to follow study procedures or complete the study;
* the use of any antidepressant medications within 5 half-lives of randomization;
* women of child-bearing potential who will not agree to use approved means of birth control during the trial;
* other reason that the primary investigator believes that the subject will be unable to complete trial or has medical/psychiatric contraindications to the trial.
* Individuals who are currently being treated for depression and show significant improvements in their depression such that discontinuing their current antidepressant therapy would likely have negative clinical consequences will be excluded from participating in this study.
* Individuals who are or become suicidal will be excluded from this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No